P
Peter J. Barnes
Researcher at National Institutes of Health
Publications - 1554
Citations - 177909
Peter J. Barnes is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Asthma & COPD. The author has an hindex of 194, co-authored 1530 publications receiving 166618 citations. Previous affiliations of Peter J. Barnes include University of Nebraska Medical Center & Novartis.
Papers
More filters
Journal ArticleDOI
A Comparison of Low-Dose Inhaled Budesonide plus Theophylline and High-Dose Inhaled Budesonide for Moderate Asthma
David J. Evans,David A. Taylor,O Zetterstrom,Kian Fan Chung,Brian J. O'Connor,Peter J. Barnes +5 more
TL;DR: The addition of low-dose theophylline to inhaled glucosteroid may be preferable to and cheaper than increasing the dose of inhaling glucosteroids in patients with moderate asthma and persistent symptoms.
Journal ArticleDOI
The cytokine network in chronic obstructive pulmonary disease.
TL;DR: There are several therapeutic approaches that target cytokine-mediated inflammation in chronic obstructive pulmonary disease, but blocking specific cytokines may not provide clinical benefit, whereas broad-spectrum anti-inflammatory approaches are more likely to be clinically effective.
Journal ArticleDOI
Efficacy and safety of inhaled corticosteroids in asthma. Report of a workshop held in Eze, France, October 1992.
Peter J. Barnes,Søren Pedersen +1 more
TL;DR: Inhaled glucocorticosteroids have now become first-line therapy for the treatment of chronic asthma in many countries as mentioned in this paper, and they are the most effective asthma therapy currently available, and numerous studies have documented their longterm efficacy in asthma control in adults and in children.
Journal ArticleDOI
Expression of Inducible Nitric Oxide in Human Lung Epithelial Cells
Richard A. Robbins,Peter J. Barnes,David R. Springall,John B. Warren,O.J. Kwon,Lee D.K. Buttery,Amanda Wilson,David A. Geller,J.M. Polak +8 more
TL;DR: It is demonstrated that cytokines, such as those released by mononuclear cells, can induce lung epithelial iNOS expression and NO release, and that this is attenuated by dexamethasone.
Journal ArticleDOI
As-Needed Budesonide–Formoterol versus Maintenance Budesonide in Mild Asthma
Eric D. Bateman,Helen K. Reddel,Paul M. O'Byrne,Peter J. Barnes,Nanshan Zhong,Christina Keen,Carin Jorup,Rosa Lamarca,Agnieszka Siwek-Posluszna,J. Mark FitzGerald +9 more
TL;DR: In patients with mild asthma, budesonide–formoterol used as needed was noninferior to twice‐daily budesonides maintenance therapy with respect to the rate of severe asthma exacerbations during 52 weeks of treatment but was inferior in controlling symptoms.